In a randomized, controlled trial involving injection-drug users in Thailand, tenofovir reduced the risk for HIV infection.
Antiretroviral pre-exposure prophylaxis (PrEP) is effective in preventing sexually acquired HIV infection among men who have sex with men as well as heterosexual men and women. Might it also help to prevent HIV infection among injection-drug users? To find out, investigators from the CDC and the Thailand Ministry of Health conducted a study involving HIV-uninfected injection-drug users recruited at drug-treatment clinics in Bangkok.
A total of 2413 individuals were randomized to oral tenofovir or placebo, either administered daily via directly observed therapy (DOT) or provided at monthly visits. The decision to use DOT was up to the participants, who could switch at monthly visits. Each month during follow-up (mean duration, 4 years), parti…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)